Showing results (171-180 of 285) with videos related to
Sort By:
Pageof 29
Hepatology (Baltimore, Md.)|April 2, 2009
Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis BMaurizia Rossana Brunetto, Francesco Moriconi, Ferruccio Bonino, et al.Antiviral Therapy|July 7, 2009
Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirinMichelle Martinot-Peignoux, Sarah Maylin, Rami Moucari, et al.European Journal of Gastroenterology & Hepatology|March 9, 2013
Insulin resistance: a major factor associated with significant liver fibrosis in Egyptian patients with genotype 4 chronic hepatitis CAhmed El Ray, Tarik Asselah, Rami Moucari, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 17, 2007
Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis BEmmet B Keeffe, Stefan Zeuzem, Raymond S Koff, et al.Journal of Hepatology|January 18, 2015
Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4Christophe Moreno, Christophe Hezode, Patrick Marcellin, et al.Annals of Internal Medicine|March 5, 2004
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin doseStephanos J Hadziyannis, Hoel Sette, Timothy R Morgan, et al.Digestive Diseases and Sciences|September 3, 2014
Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis BNaoky C Tsai, Patrick Marcellin, Maria Buti, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 7, 2011
Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3Samir R Shah, Keyur Patel, Patrick Marcellin, et al.Lancet (London, England)|April 4, 2015
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trialChristophe Hézode, Tarik Asselah, K Rajender Reddy, et al.Hepatology (Baltimore, Md.)|December 31, 2008
Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patientsRami Moucari, Vincent Mackiewicz, Olivier Lada, et al.Pageof 29